New study tests bone tumor drug in chinese patients

NCT ID NCT04586660

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 4 study tests the drug XGEVA (denosumab) in 36 Chinese adults and teens with giant cell tumor of bone, a rare but aggressive bone tumor. Participants receive injections every 4 weeks. The goal is to see if the drug shrinks tumors or helps make surgery easier. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Denosumab (XGEVA)
What this could lead to: If successful, this could confirm that denosumab helps shrink or control giant cell tumors of the bone in Chinese patients, offering a non-surgical option.
What could go wrong: This is a small, single-country study (36 participants) with no placebo group. Results may not apply to other populations, and long-term risks like jaw problems or low calcium levels are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIANT CELL TUMOR OF BONE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone giant cell tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GIANT CELL TUMOR OF BONE

Contacts and locations

Locations

Beijing Jishuitan Hospital

Beijing, Beijing Municipality, 100035, China
Harbin Meidical University Cancer Hospital

Harbin, Heilongjiang, 150000, China
National Taiwan University Hospital

Taipei, 10002, Taiwan
Peking University Peoples Hospital

Beijing, Beijing Municipality, 100044, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510663, China
Taipei Veterans General Hospital

Taipei, 11217, Taiwan
Tangdu Hospital of Air Force Medical University

Xi'an, Shaanxi, 710032, China
The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, 350005, China
The Second Affiliated hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310052, China
The Third Affiliated Hospital Of Southern Medical University

Guangzhou, Guangdong, 510630, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.